News

Enlarge image

BusinessNorway

Clavis' 2nd lead failed

03.04.2013 - Clavis Pharma has become a target for a take-over after its cancer drug delivery technology failed proof-of-concept for the second time.

In November, US partner Clovis Oncology said it will terminate its partnership with the Norwegian drug developer after CP-4126 , a liposomal formulation of the chemotherapeutic gemcitabine, failed to prove superiority to the original drug in a Phase IIb study. Yesterday, the company’s second lead, elacytarabine, fell through in a pivotal Phase III study on 380 patients with refractory blood cancer AML.

Median survival in the elacytarabine arm was 3.5 months, compared to 3.3 months in the control arm. Adverse events were comparable between the two arms, and no meaningful differences were observed in any subgroup analyses. “We will review the strategic options for the company during the coming weeks, and shareholders will be informed about the alternatives available at a later date. Immediate steps will be taken to minimise our expenditure going forward, while caring for those patients who are still benefiting from elacytarabine,“ said CEO Olaf Hellboe.

All studies with the compound have been suspended. Hellboe announced that Clavis has a short-list of private Scandinavian firms that may be interested in a take-over of the public company. "We have taken two products all way through development with lipid technology and both failed in the big final test," said Helleboe. "That means it will be very difficult to justify putting huge investments in another product with the same technology.“

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/clavis-2nd-lead-failed.html

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

FinancingSwitzerlandEU

29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Clinical ResearchFrancePortugal

21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.

Immuno-oncologyNetherlandsBelgium

21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.

RegulatorySwitzerlandEU

20.04.2016 The US government is forking out up to US$100m to get Basilea Pharmaceutica’s broad-spectrum antibiotic ceftobiprole on the US market. In the EU, ceftobiprole is already available.

Immuno-oncologyUK

19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.

FinancingSwitzerlandFranceEUGermanyDenmark

15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.

Event ReviewSwitzerlandBelgiumEU

13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.

FinancingGermanyNetherlandsEU

12.04.2016 German-Dutch life science investment specialist Forbion Capital Partners has raised more than €180m for its venture capital fund Forbion Capital Fund III. Once more the money will primarily go to European start-ups.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

München

BioVaria 2016

Berlin (GER)

XIV. BIONNALE 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • IMMUNICUM AB (S)29.80 SEK12.88%
  • PLETHORA (UK)3.38 GBP12.67%

FLOP

  • THERAMETRICS (CH)0.02 CHF-33.33%
  • BIONOR PHARMA (N)0.73 NOK-7.59%
  • ACTIVE BIOTECH (S)10.20 SEK-5.12%

TOP

  • AB SCIENCE (F)17.91 EUR62.8%
  • SYNAIRGEN (UK)35.75 GBP45.9%
  • BIOFRONTERA (D)3.19 EUR36.9%

FLOP

  • THERAMETRICS (CH)0.02 CHF-50.0%
  • SERODUS (N)1.41 NOK-31.2%
  • OREXO (S)48.80 SEK-21.3%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)30.50 SEK1974.8%
  • NICOX (F)8.88 EUR369.8%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.30 SEK-87.6%
  • BB BIOTECH (D)46.44 EUR-82.3%
  • BIOTEST (D)16.65 EUR-76.5%

No liability assumed, Date: 02.05.2016